login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Catheter ablation of ventricular tachycardia in patients with ARVD/C significantly reduces the burden of ventricular tachycardia


Wednesday, 25 Apr 2012 16:52
Harikrishna Tandri
Harikrishna Tandri


In Circulation: Arrhythmia and Electrophysiology, Binu Philips (Division of Cardiology, Department of Medicine, The Johns Hopkins Hospital, Baltimore, USA) and co-authors reported that catheter ablation is an important treatment option for the management of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) as, although ventricular tachycardia recurrences are common, the treatment reduces burden of ventricular tachycardia


Philips et al wrote that the aim of their study included determining whether catheter ablation outcomes for ARVD/C have improved with the use of electroanatomic mapping systems and epidcardial ventricular tachycardia ablation and investigating the impact of catheter ablation on the burden of ventricualr tachycardia.

They found, in a matched cohort (for age, 3D mapping technique, repetition of procedure, and centre performing catheter ablation) involving 10 epdicardial procedures and eight endocardial procedures, that ventricular tachycardia free survival was significantly longer with epicardial catheter ablation compared with endocardial catheter ablation (p=0.003). Additionally, ventricular tachycardia free survival was significantly longer in patients in whom 3D electroanatomic mapping system was used for the ablation procedure. Philips et al reported: “Freedom from ventricular tachycardia following a single ablation procedure facilitated by 3D electroanatomical mapping was 50%, 34%, and 24% compared to 36%, 16%, and 8% following a single ablation procedure not facilitated by 3D electroanatomical mapping at one, two, and five years, respectively (p=0.016).

However, whichever technique was used and whether or not a 3D-electroanatimocal mapping system was used, the rate of ventricular tachycardia reccurrence was high. Philips et al wrote: “Recurrence of ventricular tachycardia after catheter ablation is not uncommon in ARVD/C and emphasises the fact that catheter ablation cannot be considered to be ‘curative’ in the long term and should not be viewed an alternative to placement of an implantable cardioverter defibrillator.”

Despite the high rate of recurrence of ventricular tachycardia following an ablation procedure, according to Philips et al, catheter ablation should still be “viewed as an important treatment option” for patients with ARVD/C because it reduces ventricular tachycardia burden. They reported: “The mean frequency of ventricular tachycardia was significantly lower after ventricular tachycardia ablation [0.2±0.4 (median 0.08) ventricular tachycardia episodes/month] as compared with ventricular tachycardia frequency prior to ablation [0.4±0.5 (median 0.16) ventricular tachycardia episodes/month].” They added that with epicardial catheter ablation, mean ventricular tachycardia burden was reduced from 0.42±0.4 (median 0.2) episodes per month prior to the ablation procedure to 0.05±0.1 (median 0) episodes per month after the procedure.

Philips et al wrote that catheter ablation was also an important treatment option for patients who “experience intolerant side effects to antiarrhythmic medications or prefer not to take antiarrhythmic medications.” They added that while epicardial ablation was more efficacious than endocardial procedures, “it should generally be considered after a prior failed endocardial procedure given the higher complication rates associated with pericardial access, mapping, and ablation.”

 

Harikrishna Tandri, Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, USA, told Cardiac Rhythm News: “The main highlight of our study is that overall the outlook for catheter ablation in ARVD related ventricular tachycardia has significantly improved over the last five years. This is due to multiple factors including improved understanding of the disease process, use of advanced imaging techniques, substrate based ablation, epicardial ablation approach and improved operator experience with complex ventricular tachycardia ablations. An initial conservative endocardial ablation is probably appropriate for low volume centres that routinely do not perform epicardial ablations. However, to achieve best results and to minimise procedural complications, we believe that ARVD patients should be dealt with at high volume ventricular tachycardia ablation centres with particular expertise in epicardial ablation procedures".





Add New Comment

Most popular


FDA approves Attain Performa quadripolar lead and Viva Quad CRT-Ds
Thursday, 07 Aug 2014
Medtronic has received US Food and Drug Administration (FDA) approval for the Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronisation therapy ... FDA approves Attain Performa quadripolar lead and Viva Quad CRT-Ds

Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
Wednesday, 27 Aug 2014
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary ... Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

The incidence of sudden death in heart transplant patients has not improved over the last three decades
Friday, 01 Aug 2014
A first, large multicentre study in the United States has found that despite the advances in clinical management strategies after heart transplantation, there has not been an improvement in the ... The incidence of sudden death in heart transplant patients has not improved over the last three decades

Features


Antithrombotic therapy after left atrial appendage closure
Wednesday, 10 Sep 2014
Uncertainty exists about the optimal post-interventional antithrombotic drug regimen as well as treatment duration after left atrial appendage closure; Boris Schmidt and KR Julian Chun review ... Antithrombotic therapy after left atrial appendage closure

Transseptal endocardial CRT: An evolving approach for heart failure patients
Friday, 29 Aug 2014
Néstor López Cabanillas and Elencwajg Benjamin from Buenos Aires, Argentina, write about two similar novel techniques for cardiac resynchronisation therapy (CRT) implantation, currently used in some ... Transseptal endocardial CRT: An evolving approach for heart failure patients

Profiles


Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Richard Fogel
Thursday, 08 May 2014
Richard Fogel, president-elect of the Heart Rhythm Society and chief executive officer at St V... Richard Fogel

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions